Stock SEEL SEELOS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Seelos Therapeutics, Inc.

Equities

SEEL

US81577F2083

Market Closed - Nasdaq
Other stock markets
 16:30:01 2024-05-03 EDT 		5-day change 1st Jan Change
0.3393 USD +2.82% Intraday chart for Seelos Therapeutics, Inc. +16.60% -75.59%
04-29 Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors CI
03-19 Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected
Seelos Therapeutics' ALS treatment fails in mid-stage study
Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)
Seelos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%
Seelos Therapeutics Launches Registered Direct Offering, Concurrent Private Placement
Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002
Sector Update: Health Care Stocks Gain Premarket Tuesday
Seelos Therapeutics Files $250 Million Mixed Shelf
Seelos Therapeutics Insider Bought Shares Worth $100,223, According to a Recent SEC Filing
Sector Update: Health Care Stocks Mixed Late Afternoon
Sector Update: Health Care
Top Midday Decliners
Top Premarket Decliners
Seelos Therapeutics Prices Common Stock Offering
Seelos Therapeutics Commences Common Stock Offering
Seelos Therapeutics, Inc. Announces the Selection of SLS-002 (intranasal Racemic Ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder
Top Decliners
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SEEL Stock
  4. News Seelos Therapeutics, Inc.
  5. Other languages